Tag: Se-Meng Cheng
TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa
TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of ... Read More